Entrar/Registro  
INICIO ENGLISH
 
Revista de Investigación Clínica
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista de Investigación Clínica >Año 2013, No. 2


Cesarman-Maus G, Meillón L, Volkow P, Vargas-Ruiz ÁG, Cornejo P, OLópez-Navarro O, Cruz MM, Coronel O, García-Fernández L, Ochoa-Carrillo FJ, Siñani M, Baz P, Izaguirre R
Tratamiento de cáncer y trombosis: enfoque práctico
Rev Invest Clin 2013; 65 (2)

Idioma: Español
Referencias bibliográficas: 58
Paginas: 174-182
Archivo PDF: 155.42 Kb.


Texto completo




RESUMEN

Los individuos con cáncer tienen mayor riesgo de desarrollar enfermedad tromboembólica venosa. La prevalencia depende de factores relacionados con la neoplasia, como el tipo histológico, el estadio, el empleo de catéteres venosos centrales, el tratamiento con quimioterapia o radioterapia, el tipo de cirugía, así como factores protrombóticos generales que incluyen edad, inmovilización, obesidad, trombofilias hereditarias y comorbilidades. El tratamiento de individuos con trombosis venosa debe ser personalizado e integral y depende tanto del riesgo de trombosis como de hemorragia. En esta revisión se actualizan conceptos que han cambiado sustancialmente en los últimos años, como la indicación de reposo absoluto en pacientes con trombosis reciente o de dietas libres en alimentos verdes. Se proponen estrategias terapéuticas basadas en evidencia sobre los problemas clínicos encontrados con mayor frecuencia en pacientes con cáncer y trombosis.


Palabras clave: Cáncer, Trombosis, Tratamiento.


REFERENCIAS

  1. Haddad C, Greeno W. Chemotherapy-induced thrombosis. Thromb Res 2006; 118: 555-68.

  2. Prandoni P, Falanga A, PiccioliA. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-10.

  3. Cronin G, Lohan G, Keane M, Roche C, Murphy M. Prevalence and Significance of Asymptomatic Venous Thromboembolic Disease Found on Oncologic Staging CT. Amer J Roentgenol 2007; 189: 162-70.

  4. Buller HR, Van Doormaal FF, Van Sluis GL, KamphuisenW. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; 5: 246-54.

  5. Khorana A, Francis W, Culakova E, Fisher I, Kudeder M, Lyman H. Thromboembolism in Hospitalized Neutropenic Cancer Patients. J Clin Oncol 2006; 24: 484-90.

  6. Levitan N, Dowlatu A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 1999; 78: 285-91.

  7. Rak J, Yu JL, Luyendyk J, Mackman N. Oncogenes, Trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 15: 10643-6.

  8. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol 2010; 28: 132-5.

  9. Ku H, White H, Chew K, Harvey J, Zhou H, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009; 113: 3911-7.

  10. Eastman ME, Khorsand M, Maki DG, Williams EC, Kim K, Sondel PM, et al. Central venous device-related infection and thrombosis in patients treated with moderate dose continuousinfusion interleukin-2. Cancer 2001; 91: 806-14.

  11. Cornejo P, Volkow P, Aguilar JL, Villa R, Miranda Y, Cesarman- Maus G. Trombosis asociada a catéter en pacientes con cáncer de mama. Rev de Hematología 2011; 12: 229.

  12. Debourdeau P, KassabChahmi D, Le Gal G, Kriegel I, Desruennes E, Douard M-C, Elalamy I, et al. On behalf of the working group of the SOR. 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Ann Onc 2009; 20: 1459-71.

  13. Heaton DC, Han DY, Inder A. (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002; 32: 84-8.

  14. Levine M. Catheter-Associated Thrombosis: Thromboprophylaxis or Not. J Clin Oncol 2005; 18; 4006-08.

  15. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer. J Clin Oncol 2005; 23: 4063-9.

  16. Luciani A, Clement O, Halimi P, Goudot D, Portier F, Bassot V, et al. Catheter-related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Prospective Study Based on Doppler US1. Radiology 2001; 220: 655-60.

  17. Farge D, Durant C, Villiers S, Long A, Mahr A, Marty M, et al; Groupe Francophone Thrombose et Cancer (GFTC). Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Thromb Res 2010; 125: S108-S116.

  18. Fagnani D, Franchi R, Porta C, Pugliese P, Borgono K, Bertolini A, et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. Ann Oncol 2007; 18: 551-5.

  19. Sousou T, Khorana A. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-20.

  20. Khorana A, Kuderer M, Culakova E, Lyman, Francis W. Development and validation of a predictive model for chemotherapy- associated thrombosis. Blood 2008; 111: 4902-07.

  21. Shivakumar SP, Anderson DR, Couban S. Catheter-Associated Thrombosis in Patients With Malignancy. J Clin Oncol 2009; 27: 4858-64.

  22. Frasca D, Dahyot-Fizelier C, Mimoz Olivier. Prevention of central venous catheter-related infection in the intensive care unit. Critical Care 2010; 14: 212.

  23. Van Rooden CJ, Schippers EF, Guiot F.L, Barge RM, Hovens M.C, Van der Meer JM, et al. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol 2008; 26: 428-33.

  24. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Carvanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomized, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-9.

  25. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-6.

  26. Mateos M. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev 2010; 36: S24-S32.

  27. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in patients with Multiple myeloma treated with thalidomide: A Phase III, Open-Label, Randomized Trial. J Clin Oncol 2011; 29: 986-93.

  28. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood 2012; 119: 933-9.

  29. Cesarman-Maus G, Braggio E, Maldonado H, Fonseca R. Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma. Leukemia 2012. Doi: 10.1038/leu.2012.43. [Epub ahead of print].

  30. Lyman H, KhoranaA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. J Clin Oncol 2007; 25: 5490-505.

  31. Venous Tromboembolic Disease. NCCN GUIDELINES. Version 1.2012; VTE-c.

  32. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141: e419S-e494S.

  33. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of Prophylaxis against VTE with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-80.

  34. Streiff M. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of thromboembolism in cancer patients. Thromb Res 2010; S128-S133.

  35. Mandalà M, Falanga A, Roila F; On behalf of the ESMO Guidelines Working Group Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations. Ann Oncol 2009; 20: iv182-iv184.

  36. Mandalà M, Labianca R; European Society for Medical Oncology. Venous Thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management. Thromb Res 2010; 125: S117-S119.

  37. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.

  38. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27: 4895-901.

  39. Agnes YY. Lee, Treatment of Venous Thrombosis. En: Rosen ST, Green D, Kwaan HC. Springer. Coagulation in cancer. 1st Ed. Chicago, Illinois, EUA; 2009, p. 243-57.

  40. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg 2002; 36: 704-07.

  41. ShivakumarP, Andersond R, Couban S. Catheter-Associated Thrombosis in Patients With Malignancy. J Clin Oncol 2009; 27: 4858-64.

  42. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007; 5: 1650-3.

  43. Gerber DE, Grossman SA, Streiff MB. Management of Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors. J Clin Oncol 2006; 24: 1310-8.

  44. Schiff David, Deangelis Lisa. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73: 493-8.

  45. Herishanu Y, Misgav M, Kirgner I, Ben-Tal O, Eldor A, Naparstek E. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 2004; 45: 1407-11.

  46. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9thed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141: e44S-e88S.

  47. Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 2010; 104: 755-9.

  48. Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005; 93: 872-5.

  49. Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, et al. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res 2006; 76: 65-74.

  50. Sconce E, Avery P, Wynne H, Kamali F. Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 2007; 109: 2419-23.

  51. Aissaoui N, Martins E, Mouly S, Weber S, Meune C. A metaanalysis of bed rest versus early ambulation in the management of pulmonary embolism, deep vein thrombosis or both. Int J Cardiol 2009; 137: 37-41.

  52. Trujillo-Santos AJ, Martos-Pérez F, Perea-Milla E. Bed rest or early mobilization as treatment of deep vein thrombosis: a systematic review and meta-analysis. Med Clin 2004; 122: 641-7.

  53. Anderson CM, Overend TJ, Godwin J, Sealy Christina, Sunderji A. Ambulation after deep vein thrombosis: a systematic review. Physiother Can 2009; 61: 133-40 [Epud].

  54. Levine, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost 2012; 10: 807-14.

  55. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al., for the ADOPT Trial Investigators Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. N Engl J Med 2011; 365: 2167.

  56. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: MAGELLAN subgroup analyses. J Thromb Haemost 2011; 9: Abstract 034.

  57. Verso M, Agnelli G. New and old anticoagulants in cancer. Thromb Res 2012; 129: S101-S105.

  58. Weitz JI, Eikelboom JW, Samama MM. New Antithrombotic Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. CHEST 2012; 141: e120S-e151S.



>Revistas >Revista de Investigación Clínica >Año2013, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019